Vor Ort
Merkzettel Warenkorb
Produktbild: Bile Acids: From Genomics to Disease and Therapy
Band 129 - 12%

Bile Acids: From Genomics to Disease and Therapy

Aus der Reihe Falk Symposium
12% sparen

139,99 € UVP 160,49 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

31.01.2003

Herausgeber

G. Paumgartner + weitere

Verlag

Springer Netherland

Seitenzahl

300

Maße (L/B/H)

24,1/16/2,5 cm

Gewicht

626 g

Auflage

2003

Sprache

Englisch

ISBN

978-0-7923-8781-7

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

31.01.2003

Herausgeber

Verlag

Springer Netherland

Seitenzahl

300

Maße (L/B/H)

24,1/16/2,5 cm

Gewicht

626 g

Auflage

2003

Sprache

Englisch

ISBN

978-0-7923-8781-7

Herstelleradresse

Springer Nature Customer Service Center GmbH
Haberstr. 7
69126 Heidelberg
DE
ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Bile Acids: From Genomics to Disease and Therapy
  • List of Principal Contributors. Preface. Pathways and regulation of bile acid synthesis; J.B. Cheng, D.W. Russell. Section I: Regulation of Gene Expression by Bile Acids. 1. The homeostatic control of bile acid biosynthesis and transport by nuclear receptors; C.J. Sinal, F.J. Gonzales. 2. Coordinated regulation of hepatobiliary transporter genes by nuclear receptors; S. Karpen. 3. Transactivation of the human OATP8 gene by the Farnesoid X Receptor/Bile Acid Receptor (FXR/BAR); G.A. Kullak-Ublick, D. Jung. Section II: Synthesis and Metabolism of Bile Acids. 4. Vitamin D receptor as a bile acid sensor; T.T. Lu, et al. 5. Molecular mechanisms of nuclear receptor regulation of bile acid synthesis; J.Y.L. Chiang, et al. 6. Manipulating the bile acid pool regulates CYP7A1 by changing FXR activation; Guorong Xu, et al. Section III: Transport of Bile Acids and Bile Secretion. 9. Mutations in the sodium-independent bile salt uptake transporter of human liver SLC21A6; J. König, et al. 10. Regulation of the rat organic anion transporting polypeptide 4 (Oatp4) by bile acids; D.Rost, et al. 11. Regulation of expression and function of the canalicular bile acid export pump; P. Meier-Abt. 12. The in-vivo and in-vitro function of human BSEP; R. Thompson. 13. Sinusoidal efflux of bile acids; H.Akita, et al. 14. Organ-specific regulation of nuclear hormone receptors and bile salt transport proteins in obstructive cholestasis; A. Bohan, et al. Section IV: Bile Acids in Disease. 22. Acquired alterations of hepatobiliary transport systems in human cholestatic liver diseases: potential targets of pharmacotherapy; M. Trauner, et al. 23. Bilary lipid composition in BRIC patients; R.H.J. Houwen, et al. 24. Mutations in MDR3 in adult onset cholangiopathy; S. Strautnieks, et al. 25. MDR3 gene mutations and cholesterol cholelithiasis; O. Rosmorduc, et al. 26. Expression and localization of hepatobiliary transporters in primary biliary cirrhosis; H. Kojima, et al. 27. Neonatal liver disease in two siblings caused by a failure to racemize (25R)trihydroxy-cholestanoic acid due to a gene mutation in 2-methylacyl-CoA racemase: Effectiveness of cholic acid therapy in preventing liver and neurological disease; K.D.R. Setchell, et al. Section V: Bile Acids in Therapy. 28. UDCA and TUDCA ameliorate hepatocyte damage caused by EtOH and acetaldehyde by different mechanisms; U. Leuschner, et al. 29. Ursodeoxycholic acid therapy affects the cytokine network and plays an immunomodulatory role in patients with primary sclerosing cholangitis and primary biliary cirrhosis; M.G. Neumann, et al. 30. Dose response of UDCA in the treatment of cholestatic disorders; G. Mazzella, et al. 31. High dose ursodeoxycholic acid in the management of primary sclerosing cholangitis; R.W. Chapman. 32. Intrahepatic cholestasis of pregnancy: a placebo controlled randomised trial of ursodeoxycholic acid vs. dexamethasone on maternal and fetal outcome and metabolism; A Glantz, et al. 33. Ursodeoxycholic acid in the chemoprevention of colon cancer; K. Kowdley. Index. Ten Additional Articles.